Cargando…

Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case

Bile duct tumor thrombus (BDTT) of a hepatocellular carcinoma (HCC) is a rare entity which was found microscopically in 1 to 9.2% of the resected specimen. A 54-year-old male was found to have a 65-mm hepatocellular carcinoma in segment VI of the liver with a huge intrahepatic bile duct tumor thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebara, Chiharu, Yamazaki, Shintaro, Moriguchi, Masamichi, Mitsuka, Yusuke, Funada, Tomoya, Higaki, Tokio, Takayama, Tadatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616869/
https://www.ncbi.nlm.nih.gov/pubmed/23521831
http://dx.doi.org/10.1186/1477-7819-11-78
_version_ 1782265179590885376
author Ebara, Chiharu
Yamazaki, Shintaro
Moriguchi, Masamichi
Mitsuka, Yusuke
Funada, Tomoya
Higaki, Tokio
Takayama, Tadatoshi
author_facet Ebara, Chiharu
Yamazaki, Shintaro
Moriguchi, Masamichi
Mitsuka, Yusuke
Funada, Tomoya
Higaki, Tokio
Takayama, Tadatoshi
author_sort Ebara, Chiharu
collection PubMed
description Bile duct tumor thrombus (BDTT) of a hepatocellular carcinoma (HCC) is a rare entity which was found microscopically in 1 to 9.2% of the resected specimen. A 54-year-old male was found to have a 65-mm hepatocellular carcinoma in segment VI of the liver with a huge intrahepatic bile duct tumor thrombus. As the main trunk of the posterior segment branched from the left bile duct, the BDTT of the posterior branch extended to the common bile duct via the left bile duct. When the posterior segment was resected along with the left lobe, the estimated remnant liver volume was less than 30%. Therefore, the patient underwent extended posterior segmentectomy with choledochotomy and all of the BDTT was removed via the common bile duct. Three months later, his serum bilirubin (6.63 mg/dL) and des-gamma-carboxy prothrombin (410 ng/mL) were re-elevated due to recurrent BDTT. A well-enhanced BDTT was observed by computed tomography (CT) at the left bile duct. Transarterial chemotherapy with cisplatin was scheduled, followed by endoscopic retrograde bile duct drainage. After four sessions of this chemotherapy, the BDTT had vanished and the tumor marker was decreased to within the normal range. The patient was stably treated with this regimen and has remained recurrence-free for five years.
format Online
Article
Text
id pubmed-3616869
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36168692013-04-05 Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case Ebara, Chiharu Yamazaki, Shintaro Moriguchi, Masamichi Mitsuka, Yusuke Funada, Tomoya Higaki, Tokio Takayama, Tadatoshi World J Surg Oncol Case Report Bile duct tumor thrombus (BDTT) of a hepatocellular carcinoma (HCC) is a rare entity which was found microscopically in 1 to 9.2% of the resected specimen. A 54-year-old male was found to have a 65-mm hepatocellular carcinoma in segment VI of the liver with a huge intrahepatic bile duct tumor thrombus. As the main trunk of the posterior segment branched from the left bile duct, the BDTT of the posterior branch extended to the common bile duct via the left bile duct. When the posterior segment was resected along with the left lobe, the estimated remnant liver volume was less than 30%. Therefore, the patient underwent extended posterior segmentectomy with choledochotomy and all of the BDTT was removed via the common bile duct. Three months later, his serum bilirubin (6.63 mg/dL) and des-gamma-carboxy prothrombin (410 ng/mL) were re-elevated due to recurrent BDTT. A well-enhanced BDTT was observed by computed tomography (CT) at the left bile duct. Transarterial chemotherapy with cisplatin was scheduled, followed by endoscopic retrograde bile duct drainage. After four sessions of this chemotherapy, the BDTT had vanished and the tumor marker was decreased to within the normal range. The patient was stably treated with this regimen and has remained recurrence-free for five years. BioMed Central 2013-03-23 /pmc/articles/PMC3616869/ /pubmed/23521831 http://dx.doi.org/10.1186/1477-7819-11-78 Text en Copyright © 2013 Ebara et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ebara, Chiharu
Yamazaki, Shintaro
Moriguchi, Masamichi
Mitsuka, Yusuke
Funada, Tomoya
Higaki, Tokio
Takayama, Tadatoshi
Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title_full Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title_fullStr Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title_full_unstemmed Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title_short Complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
title_sort complete remission by transarterial infusion with cisplatin for recurrent bile duct tumor thrombus of hepatocellular carcinoma: report of a case
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616869/
https://www.ncbi.nlm.nih.gov/pubmed/23521831
http://dx.doi.org/10.1186/1477-7819-11-78
work_keys_str_mv AT ebarachiharu completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT yamazakishintaro completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT moriguchimasamichi completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT mitsukayusuke completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT funadatomoya completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT higakitokio completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase
AT takayamatadatoshi completeremissionbytransarterialinfusionwithcisplatinforrecurrentbileducttumorthrombusofhepatocellularcarcinomareportofacase